Agilent Technologies, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a A research report →
Range $150 – $195
Price Chart
About the company
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation.
- CEO
- Padraig McDonnell
- IPO
- 1999
- Employees
- 18,200
- HQ
- Santa Clara, CA, US
AI snapshot
Six angles, distilled from the data.
The stock remains in a constructive uptrend, trading well above its 200-day average and holding near the upper end of its 52-week range. That keeps the multi-month regime bullish, with pullbacks still looking like consolidation rather than trend damage.
Street sentiment is constructive: the consensus is Buy, with a target around 174.29 versus a 177.5 median and a 195 high. Recent changes skew positive, including fresh Buy coverage and multiple target raises, while the broader mix still includes 7 Holds and 1 Sell.
The setup favors another solid report after 5 beats in the last 7 quarters, including 9.5% and 5.7% EPS surprises in the two most recent completed periods. Next-year EPS estimates are still moving higher, from 6.70 for 2027 to 6.72 for the next-year view, so shareholders should watch for margin durability and guidance tone.
Recent insider activity leans negative on discretionary signals, with two open-market sales by Director Mikael Dolsten and no open-market buys. Most of the other filings are award, vesting, or in-kind transactions, which are routine compensation flows rather than a conviction signal.
Profitability is strong, with a 53.6% gross margin, 24.5% operating margin, and 19.5% net margin. Growth is still healthy too, with revenue up 8.1% and earnings up 8.5% year over year, while free cash flow reached $1.97 billion in fiscal 2025.
Agilent’s edge is its high-margin life sciences tools franchise and recurring CrossLab services, which support steadier profitability than many diagnostics peers. At roughly 29.9x earnings, the valuation sits at a premium that assumes continued execution and steady mid-single-digit to high-single-digit growth.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $48.04B
- P/E
- 34.45
- Fwd P/E
- 25.42
- PEG
- 1.82
- P/S
- 6.71
- P/B
- 6.72
- EV/EBITDA
- 25.37
- Div Yield
- 0.58%
- Gross Margin
- 53.73%
- Op Margin
- 22.23%
- Net Margin
- 19.53%
- ROE
- 20.47%
- ROIC
- 11.88%
Latest fiscal year · YoY change
- Revenue
- $6.95B+6.7%
- Gross Profit
- $3.64B+3.1%
- Op Income
- $1.48B
- Net Income
- $1.30B+1.1%
- EPS
- $4.59+3.4%
- OCF Growth
- -11.0%
- FCF Growth
- -16.1%
- 52W High
- $182.99
- 52W Low
- $108.35
- 50D MA
- $170.62
- 200D MA
- $138.78
- Beta
- 1.24
- RSI (14)
- 46
- Avg Volume
- 2.33M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Agilent delivered a strong Q3 with broad-based core growth, margin expansion, and an increased full-year outlook, driven by better end markets, China strength, and Ignite execution.· August 26, 2026
- Q3 revenue was $1.88 billion, core growth was 7.3%, and EPS was $1.56 ex tariff refunds, up 14% year over year.
- Operating margin expanded to 27.2% ex tariff refunds, up 210 basis points year over year; gross margin was 54.9% ex refunds.
- Full-year core growth guidance rose to 5.8% to 6%, and EPS guidance rose to $6.18 to $6.21, or $6.12 to $6.15 ex tariff refunds.
- China was a major upside driver, growing 9% versus flat expectations, while pharma grew 12% and CAM grew 7%.
- Management said reshoring, replacement cycles, new product launches, and Ignite should keep momentum going into fiscal 2027.
Agilent reported Q3 revenue of $1.88 billion, up 7.3% on a core basis and 8.1% reported. Non-GAAP gross margin was 56.4%, or 54.9% excluding an approximately 160 basis point tariff refund benefit, and operating margin was 28.3%, or 27.2% ex tariff refunds, up 210 basis points year over year. EPS was $1.62 including tariff refund benefits, or $1.56 ex refunds, up 14% year over year. For the full year, Agilent now expects reported revenue of $7.49 billion to $7.51 billion, core growth of 5.8% to 6%, and EPS of $6.18 to $6.21, or $6.12 to $6.15 ex tariff refunds. Fourth-quarter guidance calls for revenue of $1.98 billion to $2.0 billion and EPS of $1.71 to $1.74. The company also reaffirmed operating cash flow of $1.6 billion to $1.7 billion, capital expenditures of about $450 million, and ended Q3 with net leverage of 1 turn.
Padraig McDonnell framed the quarter as evidence that Agilent’s transformation is compounding, not just benefiting from easier end markets. He emphasized customer intimacy, innovation, talent, and Ignite as the four pillars behind share gains and execution, and said the business is increasingly resilient across commercial, manufacturing, supply chain, and digital. His tone was confident and constructive, with repeated comments that the company is positioned to outperform and enter 2027 from a position of strength.
Adam Elinoff highlighted that the quarter beat guidance on both revenue and profitability, with currency a small 0.2% tailwind and tariff refunds benefiting gross margin by about 160 basis points and operating margin by about 110 basis points. He cited operating cash flow of $519 million, free cash flow of $439 million, $80 million of capex, $78 million of share repurchases, and $72 million of dividends, while noting $600 million of senior notes were issued alongside the Biocare acquisition. He also pointed to full-year operating margin expansion of over 100 basis points ex refunds, unchanged operating cash flow guidance of $1.6 billion to $1.7 billion, and continued discipline on pricing, supply chain, and inventory.
Analysts focused heavily on specialty CDMO, reshoring, China, and 2027 margins. Management said the CDMO business still fits a mid-teens long-term growth view, with Train C coming online next spring and about 75% of its future capacity already spoken for through POs; they said any near-term margin drag from the ramp would be mitigated through Ignite. On reshoring, Agilent said it still sees a roughly $1 billion industry opportunity through 2030 and expects to win at least one-third of it, with instrument and service demand described as incremental. Questions on China and CAM elicited comments that strength came from pharma, food, biotech, advanced materials, and AI-related demand, while Europe and chemical/energy were softer but not seen as deteriorating materially.
The bull case is that Agilent is showing broad-based demand improvement plus real execution leverage, not just a one-off recovery. Management pointed to strong momentum in China, Pharma, CAM, replacement cycles, new product launches, and reshoring, while also lifting full-year revenue and EPS guidance. They were especially upbeat on the long runway from China, CDMO capacity, and the installed-base-driven pull-through into consumables and service.
The main risks discussed were uneven end-market recovery, with Europe softer, diagnostics slightly below expectations, and chemical/energy pressured by geopolitics and delayed capex. CDMO also has timing risk: management said Q4 ATD growth should be flattish because of regulatory submission timing, and Train C will create startup costs before full revenue ramps. Tariff refunds boosted Q3 and are not assumed in Q4, and management also noted inflationary pressure from the Middle East conflict and memory chip demand.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.7%
- Shares Outstanding
- 281.97M
- Float Shares
- 281.04M
of shares held by institutions
1,172 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for A, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Buy | Oct 13, 26 | Filing → |
| Julie JohnsonHouse · TX32 | Buy | Sep 23, 25 | Filing → |
| Julie JohnsonHouse · TX32 | Sell | Sep 23, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 29, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 29, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Jul 16, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jun 17, 25 | Filing → |
| Jefferson ShreveHouse · IN06 | Sell | May 12, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Buy | May 15, 25 | Filing → |
| Julie JohnsonHouse · TX32 | Sell | Apr 1, 25 | Filing → |
| Jefferson ShreveHouse · IN06 | Buy | Apr 17, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Sell | Apr 8, 25 | Filing → |
| Julie JohnsonHouse · TX32 | Sell | Mar 3, 25 | Filing → |
| Jefferson ShreveHouse · IN06 | Sell | Mar 13, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 34.11M | ▲ 67.12K |
| Blackrock, Inc. | 25.60M | ▼ 303.66K |
| Vanguard Capital Management LLC | 18.45M | ▲ 68.83K |
| Vanguard Portfolio Management LLC | 14.44M | ▲ 89.76K |
| State Street Corp | 12.98M | ▲ 124.81K |
| Massachusetts Financial Services Co | 9.13M | ▼ 877.57K |
| T. Rowe Price Investment Management, Inc. | 7.76M | ▼ 1.24M |
| Geode Capital Management, LLC | 7.67M | ▲ 79.16K |
| Wellington Management Group Llp | 7.45M | ▲ 198.25K |
| Bank Of New York Mellon Corp | 7.04M | ▲ 1.80M |
| Fmr LLC | 6.86M | ▲ 1.79M |
| Deutsche Bank AG\ | 6.73M | ▼ 282.03K |
Held by 2,053 ETFs
Biggest fund positions in A by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | ZHANG JIANMIAO MIKE | other | 2,974 |
| Nov 17, 26 | ZHANG JIANMIAO MIKE | other | 977 |
| Nov 18, 26 | ZHANG JIANMIAO MIKE | other | 454 |
| Nov 17, 26 | MCDONNELL PADRAIG | other | 43,230 |
| Nov 17, 26 | MCDONNELL PADRAIG | other | 21,073 |
| Nov 18, 26 | MCDONNELL PADRAIG | other | 4,147 |
| Nov 17, 26 | RIEMANN ANGELICA | other | 6,210 |
| Nov 17, 26 | RIEMANN ANGELICA | other | 2,213 |
| Nov 18, 26 | RIEMANN ANGELICA | other | 844 |
| Nov 17, 26 | KIRKWOOD JONAH PREVOST | other | 6,176 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our A coverage
Recent articles, reports, and earnings notes.

Agilent Technologies (A): Replacement Cycle Momentum Builds
Agilent posted 6.3% core growth, 14% EPS growth, and raised FY26 guidance, but the stock still needs continued execution at 23.0x forward earnings.

Agilent Technologies, Inc. (A) gains on deep earnings beat
Agilent Technologies, Inc. (A) gains after a stronger-than-expected quarter, with EPS and revenue both topping estimates. Our deep-dive looks beyond the headline beat at end-market momentum, guidance lift, tariff offsets, and the demand signals behind the after-hours move.

Agilent Technologies, Inc. (A) gains on earnings beats
Agilent Technologies, Inc. (A) gains after reporting earnings beats, lifting shares 4.0% as investors react to stronger-than-expected quarterly results.
Want a deeper read on A?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Dividend Champion, Contender, And Challenger Highlights: Week Of November 22
seekingalpha.com · Nov 20
Banco Santander S.A. Acquires New Holdings in Agilent Technologies, Inc. $A
defenseworld.net · Nov 20
Agilent Announces Cash Dividend of 26.25 Cents per Share
businesswire.com · Nov 18
Will Agilent (A) Beat Estimates Again in Its Next Earnings Report?
zacks.com · Nov 18
Agilent (A) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
zacks.com · Nov 18
Agilent Technologies (A) Reports Next Week: Wall Street Expects Earnings Growth
zacks.com · Nov 16
Commonwealth Equity Services LLC Sells 3,205 Shares of Agilent Technologies, Inc. $A
defenseworld.net · Nov 16
Agilent to Participate in 9th Annual Evercore Healthcare Conference
businesswire.com · Nov 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 14, 2026 · Live quote · Not investment advice